Sanofi-aventis launches 'Amaryl M' in Egypt

The event offered a good opportunity to increase public awareness on diabetes, the second most diagnosed disease in Egypt.

Featuring the prestigious guest speakers, Dr. Salah Shelbaya, professor of internal medicine, Ain Shams University and Dr. Ibrahim El Ebrashy; head of national diabetes institute, the conference discussed some interesting topics regarding diabetes and presented the efforts done by Sanofi-aventis, to fight this chronic disease, which is considered the world's fifth leading cause of death after infections, heart disease, cancer and accidents. However, the condition is surprisingly preventable and treatable considering the number of lives it claims each year.

Marc-Antoine Lucchini; managing director, Sanofi-aventis Egypt, said:

"Sanofi-aventis strives to provide more equitable access to health care worldwide as part of its mission, culture and values. Because of its understanding that diabetes can be managed with the proper education and access to medications and healthcare, Sanofi-aventis has taken it upon itself to provide Egyptians with ample ammunition against diabetes."

Dr. Mossad Morsi, medical & regulatory affair's director, Sanofi-aventis Egypt explained that "Amaryl M" sends a message of hope to diabetics in Egypt, as it represents a new therapeutic area to fight against diabetes pandemic.

Today, Sanofi-aventis is the diabetes market leader in Egypt, having captured almost 27% of the Egyptian market with its stellar diabetes medication line. Leading Sanofi-aventis' arsenal against diabetes is its mega-brand, Amaryl M, which is the third largest brand in the pharmaceutical market and the leading oral antidiabetic.

Through launching such convenient products, adapted to patient needs, together with education, support programs and strategic partnerships with Ministry of Health and leading healthcare professionals, Sanofi-aventis managed to reach an unprecedented number of individuals needing diabetes education and treatment.

Having successfully campaigned against diabetes in all corners of the globe, Sanofi-aventis is confident that Egypt will take very significant strides in the struggle to keep its citizens safe from the threat of diabetes.